Covered recipient · General Payments record
KAUSHAL R PATEL
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$11,845.81
- Reported across 72 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $277.72 | 16 |
| Education | $27.69 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Relypsa, Inc. | $201.38 | 12 |
| Amgen Inc. | $40.64 | 2 |
| AKEBIA THERAPEUTICS INC | $24.61 | 1 |
| Ardelyx, Inc. | $22.23 | 1 |
| Retrophin, Inc. | $16.55 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | $24.61 | 10/23/2024 | Education | Undisputed | 01/23/2026 | 1145833863 | CMS |
| Amgen Inc. | $22.32 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117349163 | CMS |
| Amgen Inc. | $18.32 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117349165 | CMS |
| Ardelyx, Inc. | $22.23 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146700012 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 04/10/2024 | Education | Undisputed | 01/23/2026 | 1149906018 | CMS |
| Travere Therapeutics, Inc. | $13.47 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149906022 | CMS |
| Vifor Pharma, Inc. | $17.04 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124038962 | CMS |
| Vifor Pharma, Inc. | $1.46 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124044879 | CMS |
| Vifor Pharma, Inc. | $0.24 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124044882 | CMS |
| Vifor Pharma, Inc. | $24.67 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124044887 | CMS |
| Vifor Pharma, Inc. | $6.75 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124039790 | CMS |
| Vifor Pharma, Inc. | $8.93 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124043671 | CMS |
| Vifor Pharma, Inc. | $30.09 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124047189 | CMS |
| Vifor Pharma, Inc. | $1.20 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124047193 | CMS |
| Vifor Pharma, Inc. | $8.22 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124042234 | CMS |
| Vifor Pharma, Inc. | $8.54 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124063893 | CMS |
| Vifor Pharma, Inc. | $16.04 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124065254 | CMS |
| Vifor Pharma, Inc. | $78.20 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124062857 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.